CAJ | 학술논문

目的：探讨卵巢上皮性癌中干扰素介导的跨膜蛋白1（ IFITM1）基因的表达及其临床意义。方法应用免疫组织化学检测42例正常卵巢、51例卵巢良性肿瘤、48例卵巢交界性肿瘤和85例卵巢上皮性癌组织中IFITM1的阳性表达，同时分析IFITM1蛋白表达状况与上皮性卵巢癌各临床病理因素之间的关系。结果免疫组化显示IFITM1蛋白表达强度在正常卵巢、良性卵巢肿瘤、交界性卵巢肿瘤、上皮性卵巢癌间有统计学意义（χ2＝8．407，P＝0．004）。正常卵巢组织中IFITM1阳性表达率为40．5％（17／42），卵巢良性肿瘤组织中70．5％（36／51），卵巢交界性肿瘤组织中为70．8％（34／48），卵巢上皮性癌中为77．6％（66／85），IFITM1的阳性表达率在4种卵巢组织中比较有统计学意义（χ2＝18．491，P＜0．001）。 IFITM1在上皮性卵巢癌中的表达与FIGO分期、细胞分化程度和组织学类型性有关（χ2值分别为4．307、6．959、8．539，均P＜0．05），早期卵巢癌（Ⅰ＋Ⅱ）中IFITM1蛋白表达低于晚期卵巢癌（Ⅲ＋Ⅳ），χ2＝4．307，P＝0．038），随着肿瘤细胞分化程度的降低，IFITM1表达率逐渐增高。 IFITM1蛋白表达与淋巴转移、腹水无统计学相关性（χ2值分别为0．111、0．024，均P＞0．05）。耐药性卵巢癌中IFITM1阳性表达显著高于敏感组（χ2＝34．843，P＜0．001）。结论 IFITM1表达在卵巢上皮性癌组织中明显高于正常卵巢、卵巢良性肿瘤和卵巢交界性肿瘤，提示IFITM1参与了卵巢癌的发生和进展，并对以铂类为基础的化疗耐药性产生有临床预测价值。
목적：탐토란소상피성암중간우소개도적과막단백1（ IFITM1）기인적표체급기림상의의。방법응용면역조직화학검측42례정상란소、51례란소량성종류、48례란소교계성종류화85례란소상피성암조직중IFITM1적양성표체，동시분석IFITM1단백표체상황여상피성란소암각림상병리인소지간적관계。결과면역조화현시IFITM1단백표체강도재정상란소、량성란소종류、교계성란소종류、상피성란소암간유통계학의의（χ2＝8．407，P＝0．004）。정상란소조직중IFITM1양성표체솔위40．5％（17／42），란소량성종류조직중70．5％（36／51），란소교계성종류조직중위70．8％（34／48），란소상피성암중위77．6％（66／85），IFITM1적양성표체솔재4충란소조직중비교유통계학의의（χ2＝18．491，P＜0．001）。 IFITM1재상피성란소암중적표체여FIGO분기、세포분화정도화조직학류형성유관（χ2치분별위4．307、6．959、8．539，균P＜0．05），조기란소암（Ⅰ＋Ⅱ）중IFITM1단백표체저우만기란소암（Ⅲ＋Ⅳ），χ2＝4．307，P＝0．038），수착종류세포분화정도적강저，IFITM1표체솔축점증고。 IFITM1단백표체여림파전이、복수무통계학상관성（χ2치분별위0．111、0．024，균P＞0．05）。내약성란소암중IFITM1양성표체현저고우민감조（χ2＝34．843，P＜0．001）。결론 IFITM1표체재란소상피성암조직중명현고우정상란소、란소량성종류화란소교계성종류，제시IFITM1삼여료란소암적발생화진전，병대이박류위기출적화료내약성산생유림상예측개치。
Objective To investigate the expression and clinical implication of interferon-induced transmembrane protein 1 (IFITM1) in epithelial ovarian carcinoma.Methods The positive expression of IFITM1 was determined with SP immunohistochemistry in 42 cases of normal ovarian tissue, 51 cases of benign ovarian tumor, 48 cases of borderline ovarian tumor, and 85 cases of epithelial ovarian carcinoma.The correlation between its expression and clinical pathological factors of epithelial ovarian carcinoma was analyzed.Results The immunohistochemical technique showed that the expression levels of IFITM1 were statistically different in four kinds of tissues (χ2 =8.407,P=0.004).The positive expression rate of IFITM1 was 40.5%(17/42), 70.5%(36/51), 70.8%(34/48) and 77.6%(66/85), respectively in normal ovarian tissue, benign ovarian tumor, borderline ovarian tumor and epithelial ovarian carcinoma (χ2 =18.491, P<0.001).The expression of IFITM1 was correlated with FIGO stage, tumor grade and histological type in epithelial ovarian carcinoma (χ2 value was 4.307, 6.959 and 8.539, respectively, all P<0.05).It was lower in early stage of ovarian carcinoma (Ⅰ, Ⅱ) than in late stage (Ⅲ,Ⅳ) (χ2 =4.307,P=0.038).With the decreasing of differentiation, the expression rate of IFITM1 increased.IFITM1 was not significantly correlated with lymphatic metastasis and abdominal dropsy (χ2 value was 0.111 and 0.024, respectively, both P>0.05).The positive expression of IFITM1 in drug resistant group was significantly higher than that in sensitive group (χ2 =34.843,P<0.001).Conclusion The expression of IFITM1 is significantly higher in epithelial ovarian carcinoma than in normal ovarian tissue, benign ovarian tumor and borderline ovarian tumor, which indicates that IFITM1 may play a vital role in carcinogenesis and progression of ovarian carcinoma and that it has predictive value on resistance of platinum-based chemotherapy.